Drug intelligence / Profile preview

valproate + amisulpride

Development stage
Phase 2
Lead developer
Sanofi
Modality
Small Molecules
Administration
Oral
01

Overview

**Valproate + amisulpride** is a combination of two pharmaceutical agents used primarily for the treatment of acute mania in bipolar I disorder. Valproate is a widely used mood stabilizer and anticonvulsant that primarily increases gamma-aminobutyric acid (GABA) levels in the brain, providing mood-stabilizing and antimanic effects. Amisulpride is an atypical antipsychotic that selectively antagonizes dopamine D2 and D3 receptors, particularly in the limbic system, reducing both positive and negative psychotic symptoms and extending some antidepressant effects. Clinical studies indicate that the combination is as effective as valproate with typical antipsychotics, but with a lower rate of extrapyramidal side effects and treatment-emergent adverse events[1][2][3]. This combination is most studied as an acute therapy in adults with manic episodes associated with bipolar I disorder.

02

Targets

DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)

Beyond the preview

Go deeper on valproate + amisulpride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on valproate + amisulpride.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call